A new Ebola outbreak has been confirmed in Congo’s remote Ituri province, with 246 suspected cases and 65 deaths recorded so ...

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

The Supreme Court on Thursday preserved women’s access to the abortion drug mifepristone, rejecting lower-court ...

Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout ...

The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas ...

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates ...

This week's episode of “The Readout LOUD” is all about health politics, including Marty Makary's departure as FDA ...

At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the ...